ライフサイエンスコーパス: HCTZ

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します

1 HCTZ is the most commonly prescribed antihypertensive dr

2 ve either chlorthalidone, 6.25 mg, (n = 16); HCTZ 12.5 mg (n = 18); or HCTZ-CR 12.5 mg (n = 20).

3 More than 97% of all HCTZ prescriptions are for 12.5 to 25 mg per day.

4 ion between HCTZ 12.5 mg (5.7/3.3 mm Hg) and HCTZ 25 mg (7.6/5.4 mm Hg).

5 no significant differences between SPIRO and HCTZ.

6 tolic blood pressure with spironolactone and HCTZ but not with placebo.

7 Because HCTZ has been perceived as a short-acting drug, a third

8 astolic (p = 0.15) 24-h BP reduction between HCTZ 12.5 mg (5.7/3.3 mm Hg) and HCTZ 25 mg (7.6/5.4 mm

9 ed with the HCTZ group and with the combined HCTZ and placebo groups.

10 Although no head-to-head trials compare HCTZ with the uncommonly prescribed chlorthalidone (CTDN

11 of essential hypertension, whereas low-dose HCTZ monotherapy is not an appropriate antihypertensive

12 fferences in duration of action (16-24 h for HCTZ versus 48-72 h for CTDN).

13 arison with an extended-release formulation (HCTZ-controlled release [CR]) was added.

14 Hydrochlorothiazide (HCTZ) in the 12.5-mg dose remains the most commonly pres

15 f spironolactone 25 mg, hydrochlorothiazide (HCTZ) 12.5 mg, or placebo for 6 months.

16 ypertensive efficacy of hydrochlorothiazide (HCTZ) by ambulatory blood pressure (BP) monitoring.

17 nd 25 non-responders to hydrochlorothiazide (HCTZ) or chlorthalidone.

18 Hydrochlorthiazide (HCTZ) is the tenth most commonly prescribed drug in rece

19 cause outcome data at this dose are lacking, HCTZ is an inappropriate first-line drug for the treatme

20 The antihypertensive efficacy of HCTZ by ambulatory BP monitoring is less well defined.

21 The antihypertensive efficacy of HCTZ in its daily dose of 12.5 to 25 mg as measured in h

22 Fourteen studies of HCTZ dose 12.5 to 25 mg with 1,234 patients and 5 studie

23 o 25 mg with 1,234 patients and 5 studies of HCTZ dose 50 mg with 229 patients fulfilled the inclusio

24 6.25 mg, (n = 16); HCTZ 12.5 mg (n = 18); or HCTZ-CR 12.5 mg (n = 20).

25 04) and 0.87% (95% CI 0.03 to 1.71%) for RSG+HCTZ (P = 0.041) only.

26 SG+FRUS), (3) RSG + hydrochlorothiazide (RSG+HCTZ), (4) RSG + spironolactone (RSG+SPIRO), and (5) dis

27 In contrast to the HCTZ group, the HCTZ-CR group also showed a significant (p < 0.01) reduc

28 in the chlorthalidone group than in the the HCTZ group.

29 In contrast to the HCTZ group, the HCTZ-CR group also showed a significant

30 he spironolactone group as compared with the HCTZ group and with the combined HCTZ and placebo groups

31 were differentially expressed in relation to HCTZ or chlorthalidone BP response in whites.

32 ed trials (n = 50,946), CTDN was superior to HCTZ in reducing congestive heart failure and in reducin

33 idence demonstrates that CTDN is superior to HCTZ in reducing CVEs and is congruent with the recent c

34 significant reduction in CVEs by CTDN versus HCTZ persisted even when reduction in office SBP produce

35 tage risk reduction in CVEs from CTDN versus HCTZ was 21 [95% confidence interval (CI) 8-32], P = 0.0

36 With HCTZ therapy, sustained hypertension was converted into

37 The decrease in 24-h BP with HCTZ dose 12.5 to 25 mg was systolic 6.5 mm Hg (95% conf

38 randomized trials that assessed 24-h BP with HCTZ in comparison with other antihypertensive drugs.

39 an observational cohort study, compared with HCTZ, CTDN was associated with lower left ventricular hy

40 compared chlorthalidone, 6.25 mg daily, with HCTZ, 12.5 mg daily, by 24-h ambulatory blood pressure (

41 However, with HCTZ 50 mg, the reduction in 24-h BP was significantly h

42 re observed with chlorthalidone but not with HCTZ.

43 significant 24-h ABP reduction was seen with HCTZ, 12.5 mg daily, which merely converted sustained hy

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。